all

National Lipid Association Unveils New Mission to Advance Lipidology and Cardiometabolic Health

JACKSONVILLE, Fla. – (May 31, 2024) - The National Lipid Association (NLA) is proud to announce its renewed mission: “To enhance the science and practice of lipidology and promote optimal cardiometabolic health.” This updated mission underscores the NLA’s commitment to advancing the field of lipidology and improving health outcomes for individuals with lipid disorders.

Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and Rosenson.

The press releases with manuscript information can be accessed here.